DPL Korea Israel Life Science Fund offers an innovative life science investment opportunity by combining the best of Korea and Israel.

  • Identifies and invests in promising early pre-revenue stage Israeli life science firms.
  • Seeks outstanding Korean firms to commercialize the technology.
  • Opens Asian markets to Israeli life sciences companies.
  • It offers you, as an investor, access to the best of life science innovations from Israel, combined with commercialization and product development expertise from Korea.
  • We act as an early stage investor, typically pre-revenue, with all the opportunity to get in at the earliest possible stage and reap the largest possible gains – but, with a difference.  With three seasoned managers, the fund reduces risk by facilitating earlier liquidity events and lowers the possibility of dilution.

The Goal of the Fund is to provide you with superior returns via early-stage investing. We will invest across the Israeli life science spectrum to mitigate risk.  Our premise is simple:

  • Take the best of Israeli life sciences – Identify best of breed early stage life science companies, seeking promising technology from universities.
  • Commercialize in Korea – Identify market needs. Provide financial support to scale up. Provide management expertise. Develop and execute strategic operational and marketing plans.
  • Then, market to the rest of the world.   Plus, connect to the broader Asian market.

We’re nimble, with a relatively small size of $50 million,  the Fund has the ability to make investments in the $750k-$1.5 million range with reserves for follow-on investments.

Unique, Seasoned Team: The Fund’s founders form a potent mix of early stage venture investing, international private equity and global corporate operations.
> Marc Feldman – 30 years’ experience in private equity, M&A and international business, including serving on the Israel Desk at Shamrock Capital Advisors’ and founding their early stage life science investing program.
> Jerry Katz, Esq. – 30 years’ experience as a business lawyer and executive; Of Counsel at Glaser Weil and former Chief Operating Officer, Chief Compliance Officer and General Counsel of Marlin Equity Partners, a private equity firm with over $2.6 billion of capital under management.
> David J.W. Suh – 25+ years of experience in start-up investments, M&A, and risk management, including positions at Morgan Stanley Dean Witter, Sakura Bank, and Cambridge Capital Partners.